Latuda Articles
Sunovion files two sNDAs for Latuda with FDA
9 September 2012
Dainippon Sumitomo's Latuda meets key endpoints in two Ph III trials in bipolar I depression
9 May 2012
Sunovion’s Latuda non-inferior to AstraZeneca’s Seroquel XR in risk relapse for schizophrenia patients
30 October 2011
US FDA approves additional medical indication for Bristol-Myers Squibb’s Sprycel; clears Sunovion’s Latuda; further delays Vivus’ Qnexa
29 October 2010
Showing 1-4 of 4 articles
- 1
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
